In this issue

Jonathan Tobin: Defending the Right to a Jewish State

Heather Hale: Compliment your kids without giving them big heads

Megan Shauri: 10 ways you are ruining your own happiness

Carolyn Bigda: 8 Best Dividend Stocks for 2015

Kiplinger's Personal Finance editors: 7 Things You Didn't Know About Paying Off Student Loans

Samantha Olson: The Crucial Mistake 55% Of Parents Are Making At Their Baby's Bedtime

Densie Well, Ph.D., R.D. Open your eyes to yellow vegetables

The Kosher Gourmet by Megan Gordon With its colorful cache of purples and oranges and reds, COLLARD GREEN SLAW is a marvelous mood booster --- not to mention just downright delish
April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

7 Great Growth Stocks with Long-Term Potential

By Tom Petruno

JewishWorldReview.com | Buying shares of a growth company early in its run to greatness is the holy grail of stock picking. The goal is to get in at a relatively cheap price, hang on as revenue and earnings rise sharply, and reap big returns as other investors hop aboard. But after the stock market's phenomenal five-year bull run, finding undiscovered gems today is no easy feat.

We went hunting for attractive growth companies and came up with seven. (Bonus: We'll also tell you about four good mutual funds, in case you'd rather buy your growth stocks that way.) Our stock picks cover a broad spectrum of sizes, industries and growth rates, but they all share one trait: In the view of Wall Street analysts, their earnings will rise significantly faster than the 10.2% average annual earnings growth predicted for Standard & Poor's 500-stock index over the next three years. (The actual growth rate for the broad market will almost certainly be lower than what Wall Streetexpects.)

Having a long time horizon is key at this stage of a bull market. Buying at today's price levels may mean it will be five years or more before a stock realizes meaningful appreciation.

Walt Disney

Headquarters: Burbank, Cal.
52-week range: $60.41 - $87.63
Market capitalization: $149.1 billion
Annual sales: $45.0 billion

Estimated earnings growth (next five years): 16% Disney (DIS) remains the premier U.S. entertainment franchise, with its film studios (latest hit: Frozen), TV networks (includingABC and ESPN), theme parks, resorts, home videos and consumer products.

With $45 billion in annual revenues, Disney can't grow at the pace of smaller, up-and-coming businesses. But it offers investors the benefits of a blue-chip company that's still capable of market-beating growth. Even allowing for typical Wall Street over-optimism, there is good reason to believe that Disney's growth rate will stay above the blue-chip average.

Key to the company's success is its ESPN juggernaut. Led by the sports channels, Disney's cable networks now generate 52% of the company's total operating profit. But beyond cable, Disney'sability to consistently find new ways to make money from its treasure trove of assets--from Mickey to Buzz Lightyear and Captain America--is unparalleled in the media industry, saysMorningstar analyst Peter Wahlstrom.


Headquarters: San Diego
52-week range: $61.19 - $81.66
Market capitalization: $137.5 billion
Annual sales: $24.9 billion
Estimated earnings growth: 15%

Like Disney, Qualcomm (QCOM) knows a thing or two about managing a growth business. The company has mushroomed over the past 30 years into a global leader in wireless technologies. That puts it at the heart of the continuing rush throughout the world to be connected--to anyone and, increasingly, to anything.

Qualcomm earns technology-licensing fees on nearly every 3G and 4G wireless phone sold. The San Diego company also produces the chips that help run many high-end smart phones and tablet computers. All told, Qualcomm earned $7.9 billion, or $4.51 per share, in the fiscal year that ended last September, representing a doubling of profits since 2010. That pace isn't likely to continue, in part because Qualcomm faces rising competition.

Still, the company's size and technological know-how give it an advantage over rivals as consumers and businesses worldwide demand faster and more-intelligent wireless phones. Investors looking to play the telecom industry can certainly find smaller, faster-growing companies. But if you want a marquee name at the forefront of wireless technology, Qualcomm fits the bill.

Actavis PLC

Headquarters: Dublin, Ireland

52-week range: $124.45 - 230.77
Market capitalization: $38.0 billion
Annual sales: $8.7 billion
Estimated earnings growth: 20%

It seemed a slam-dunk in the late 1990s to bet that the giant U.S. drug companies would make a lot of money off an aging population. But stocks such as Merck and Pfizer were terrible performers in the first decade of the new century as the companies lost patent protection for key products and makers of generic drugs swooped in. Now comes generic firm Actavis PLC(ACT) with a reverse strategy: It is buying up brand-name drug makers to boost its long-term prospects by lessening its dependence on the cutthroat generic business.

Actavis, the third-largest U.S. generic drug firm, spent $8.5 billion last year to buy Ireland's Warner Chilcott, a maker of brand-name drugs to treat women's-health, gastroenterological and dermatological issues. (Actavis is headquartered in Dublin, although its executive offices are in Parsippany, N.J.) In February, Actavis announced another blockbuster acquisition: a $25 billion deal to buy Forest Laboratories, which is known for drugs that are used to treat depression, high blood pressure, fibromyalgia and other diseases.

With the mergers, Actavis' annual revenues should reach $15 billion by next year, up from just $3.6 billion in 2010. Profits will be helped in part by the low tax rate Actavis now enjoys after changing its registration to Ireland.


Headquarters: Mountain View, Cal.

52-week range: $136.02 - $257.56
Market capitalization: $20.1 billion
Annual sales: $1.5 billion
Estimated earnings growth: 35%

Love it or hate it, social media is here to stay. For investors, the question is which social-media companies are here to stay--and which are likely to flame out.

High on the list of this year's losers is professional-networking leader LinkedIn (LNKD). After peaking at $258 last fall, LinkedIn's shares have slid to $162. Besides being caught in the general rout of tech stocks, LinkedIn has spooked some investors by showing signs that its red-hot growth of the past few years is slowing. First-quarter revenues climbed 46%, to $473 million, from the same period a year earlier, but that was down from full-year growth of 57% in 2013. And after posting mostly modest quarterly profits since 2010, the company fell back into the red in the first quarter, losing $13 million as it spent heavily on expansion.

Wall Street analysts still think LinkedIn has spectacular growth potential. One reason is the 300 million people worldwide who have joined LinkedIn--in theory, at least, to enhance their career prospects. If the future of business networking and recruiting is increasingly online, LinkedIn is in a sweet spot to sell more services to both workers and employers.


Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". HUNDREDS of columnists and cartoonists regularly appear. Sign up for the daily update. It's free. Just click here.

3D Systems

Headquarters: Rock Hill, S.C.

52-week range: $43.35 - $97.28
Market capitalization: $5.8 billion
Annual sales: $513.4 million
Estimated earnings growth: 22%

Some investors may view 3D printing like flying cars: futuristic technology that will never really get here. In fact, the technology is already widely in use in manufacturing. And one of the oldest names in 3D printers, 3D Systems (DDD), has been making money since 2009. Sales have jumped from $113 million that year to$513 million in 2013.

But as so often happens, exciting new technology triggers stock manias. Shares of 3D Systems and its rivals rocketed in 2012 and 2013, with 3D Systems soaring from $10 at the start of 2012 to a peak of $97 last January. Since then, as high-flying stocks in general have crashed, 3D Systems has tumbled as well.

For growth-hunting investors who can handle high risk, however, the sinking stock price could be a gift. Though the consumer market for 3D printing remains small, many manufacturers have embraced it--not yet for mass production but for smaller tasks, such as creating prototypes and producing replacement parts for older machinery. 3D printing uses digital imagery of an object to replicate it in metal, plastic or other materials. For 3D Systems and other printer makers, long-term growth will hinge not just on printer sales but also on revenue from material refills and servicing, as with conventional printers.

Air Lease

Headquarters: Los Angeles

52-week range: $25.74 - $42.89
Market capitalization: $3.8 billion
Annual sales: $858.7 million
Estimated earnings growth: 29%

Travel is a growth industry worldwide, but it has been tough to make money in the notoriously fickle airline industry. Air Lease (AL) offers a different way to bet on travel: It buys jets and leases them to major airlines worldwide, a profitable middleman role that gives carriers greater financial and business flexibility.

Jet leasing is a tricky business because it requires financial savvy as well as the ability to ride out inevitable airline-industry turbulence. But Air Lease's chief executive, Steven Udvar-Házy, 68, has been doing this for a long time: He ran International Lease Finance Corp. from 1973 to 2010, when he left to launch Air Lease as a competitor. The new company's revenues rose from$337 million in 2011 to $859 million in 2013. Per-share earnings reached $1.80 last year, up from 59 cents in 2011.

Analysts at Morgan Stanley say Air Lease has a number of advantages over its rivals, including the youngest fleet of high-quality jets and a "relatively conservative balance sheet," which will allow the company to take on more debt. The key risks: a major economic slump or another credit crunch. But Udvar-Házy has seen those before.

IPG Photonics

Headquarters: Oxford, Mass.

52-week range: $53.28 - $79.00
Market capitalization: $3.2 billion
Annual sales: $648.0 million
Estimated earnings growth: 26%

IPG Photonics (IPGP) isn't a household name, but it's a big one in the business of lasers. After four years of rapid growth, the company appears to have hit a soft patch in sales. If this setback is just a hiccup, it could be a great opportunity for long-term investors, with the stock down 21% from its 2013 high.

IPG says it's the world's leading producer of high-performance lasers used in manufacturing, telecommunications, health care and other applications. The majority of sales are to manufacturers for use in materials processing--for example, cutting, drilling and welding metals or other materials. Using a term favored by Silicon Valley, IPG sees itself in the role of a "disruptor," as its lasers replace older technologies in manufacturing. IPG's revenues jumped from $186 million in the recession year of 2009 to $648 million in 2013; earnings per share rocketed from 12 cents to$2.97 in the same period.

The firm is facing competition from China in lower-end lasers, but with $481 million in cash on its balance sheet and little debt, it has the wherewithal to power ahead.

Best of the Growth Funds

If you'd rather buy growth stocks through a fund, start by checking out two members of the Kiplinger 25. At Fidelity New Millennium (symbol FMILX), manager John Roth invests in a diverse mix of companies, including emerging growers and out-of-favor firms. Stocks of large companies account for 59% of the fund's assets; midsize and small outfits make up the rest. Despite its name, Baron Small Cap (BSCFX) has slightly more of its assets invested in midsize firms than in small-capitalization issues. Manager Cliff Greenberg, who favors undervalued growth companies, has mostly stayed away from high-flying social-media and biotech stocks.

Also worthy of consideration is Primecap Odyssey Growth (POGRX), a team-run fund managed by low-profile Primecap Management. The fund's performance has been plenty high-profile: From 2005, Odyssey Growth's first full year, through 2013, it landed in the top third of the large-cap growth category six times. Annual expenses are 0.65%, unusually low for an actively managed fund.

If you prefer an exchange-traded fund, look no further than PowerShares QQQ (QQQ). One of the oldest ETFs, QQQ tracks the Nasdaq 100 index and holds many tech giants, including Apple,Google and Facebook. Annual fees are 0.20%.

Sign up for the daily JWR update. It's free. Just click here.

Interested in a private Judaic studies instructor — for free? Let us know by clicking here.

Tom Petruno is a Contributing Writer for Kiplinger's Personal Finance magazine.

All contents copyright 2013 The Kiplinger Washington Editors, Inc. Distributed by Tribune Content Agency, LLC